Exact Sciences Q1 EPS Forecast Reduced by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Investment analysts at Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for Exact Sciences in a research note issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of ($0.14) per share for the quarter, down from their prior forecast of ($0.06). The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences' Q2 2025 earnings at ($0.01) EPS and FY2025 earnings at $0.20 EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million during the quarter, compared to analysts' expectations of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%.

EXAS has been the topic of several other reports. Benchmark restated a "buy" rating and issued a $65.00 price target on shares of Exact Sciences in a research report on Monday, January 13th. Guggenheim restated a "buy" rating and set a $60.00 target price on shares of Exact Sciences in a research report on Friday, April 11th. Royal Bank of Canada assumed coverage on shares of Exact Sciences in a research report on Thursday, March 13th. They issued a "sector perform" rating and a $52.00 price target on the stock. Barclays reduced their price objective on shares of Exact Sciences from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Finally, William Blair reaffirmed an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 20th. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Exact Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $69.25.

Exact Sciences Trading Down 0.5 %

EXAS stock traded down $0.25 during midday trading on Wednesday, reaching $45.21. The company's stock had a trading volume of 440,923 shares, compared to its average volume of 2,600,176. The business's 50-day simple moving average is $45.34 and its 200-day simple moving average is $54.01. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. Exact Sciences has a 52 week low of $39.97 and a 52 week high of $72.83. The stock has a market cap of $8.40 billion, a PE ratio of -8.12 and a beta of 1.14.

Institutional Trading of Exact Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Asset Planning Inc acquired a new position in shares of Exact Sciences during the 4th quarter worth approximately $40,000. Modus Advisors LLC acquired a new stake in Exact Sciences in the fourth quarter valued at $43,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Exact Sciences in the 1st quarter valued at about $34,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Exact Sciences during the 4th quarter worth about $45,000. Finally, AlphaQuest LLC raised its holdings in shares of Exact Sciences by 22,825.0% in the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock valued at $52,000 after purchasing an additional 913 shares during the period. Institutional investors and hedge funds own 88.82% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.